Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.
Soumya Paul
Advertisement
Soumya Paul is CEO at Pentavalent Biosciences.
Articles by Soumya Paul
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
4
Dostarlimab-gxly Wins FDA Accelerated Approval in Rectal Cancer
5